Announcement PDF Appendix 3Y Change of Director’s Interest Notice + See chapter 19 for defined terms. 01/01/2011 Appendix 3Y Page 1 Rule 3.19A.2 Appendix 3Y Change of Director’s Interest Notice Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX’s property and may be made public. Introduced 30/09/01 Amended 01/01/11 Name of entity LTR Pharma Limited ABN 42 103 087 449 We (the entity) give ASX the following information under listing rule 3.19A.2 and as agent for the director for the purposes of section 205G of the Corporations Act. Name of Director Maja McGuire Date of last notice 9 December 2024 Part 1 - Change of director’s relevant interests in securities In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust Note: In the case of a company, interests which come within paragraph (i) of the definition of “notifiable interest of a director” should be disclosed in this part. Direct or indirect interest Indirect Nature of indirect interest (including registered holder) Note: Provide details of the circumstances giving rise to the relevant interest. Maja Mcguire <Scaraf A/C> Date of change 19 November 2025 No. of securities held prior to change 100,000 Unlisted Options exercisable at $2.52 per option expiring 2 December 2028 235,492 Fully Paid Ordinary Shares 500,000 Unlisted Options exercisable at $0.22 per option expiring 31 October 2028 Class Unlisted Options Number acquired 1,000,000 Number disposed Not applicable Value/Consideration Note: If consideration is non-cash, provide details and estimated valuation Nil consideration Appendix 3Y Change of Director’s Interest Notice + See chapter 19 for defined terms. Appendix 3Y Page 2 01/01/2011 No. of securities held after change 100,000 Unlisted Options exercisable at $2.52 per option expiring 2 December 2028 1,000,000 Unlisted Options exercisable at $0.5075 per option expiring 24 October 2029 235,492 Fully Paid Ordinary Shares 500,000 Unlisted Options exercisable at $0.22 per option expiring 31 October 2028 Nature of change Example: on-market trade, off-market trade, exercise of options, issue of securities under dividend reinvestment plan, participation in buy- back Issue of 1,000,000 Unlisted Options under the Employee Incentive Plan as approved by shareholders at the Company’s 2025 Annual General Meeting (Resolution 9) Part 2 – Change of director’s interests in contracts Note: In the case of a company, interests which come within paragraph (ii) of the definition of “notifiable interest of a director” should be disclosed in this part. Detail of contract Not applicable Nature of interest Not applicable Name of registered holder (if issued securities) Not applicable Date of change Not applicable No. and class of securities to which interest related prior to change Note: Details are only required for a contract in relation to which the interest has changed Not applicable Interest acquired Not applicable Interest disposed Not applicable Value/Consideration Note: If consideration is non-cash, provide details and an estimated valuation Not applicable Interest after change Not applicable Part 3 – +Closed period Were the interests in the securities or contracts detailed above traded during a +closed period where prior written clearance was required? No Appendix 3Y Change of Director’s Interest Notice + See chapter 19 for defined terms. 01/01/2011 Appendix 3Y Page 3 If so, was prior written clearance provided to allow the trade to proceed during this period? Not applicable If prior written clearance was provided, on what date was this provided? Not applicable